Bull case
PM would need investors to value it at roughly 26x earnings — about 6x more generous than today's 20x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Three scenarios for where PM stock could go
PM would need investors to value it at roughly 26x earnings — about 6x more generous than today's 20x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
At 23x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
If investor confidence fades or macro conditions deteriorate, a 6x multiple contraction could push PM down roughly 28% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.

Philip Morris International is a global tobacco company transitioning from traditional cigarettes to smoke-free alternatives like heated tobacco and vaping products. It generates revenue primarily from cigarette sales — still about two-thirds of total — with the remainder from smoke-free products sold in over 70 markets worldwide. The company's key advantage is its dominant Marlboro brand equity and extensive international distribution network, which it leverages to convert smokers to its higher-margin smoke-free portfolio.
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $1.91/$1.86 | +2.7% | $10.1B/$10.3B | -1.7% |
| Q4 2025 | $2.24/$2.09 | +7.2% | $10.8B/$10.6B | +2.0% |
| Q1 2026 | $1.70/$1.70 | +0.0% | $10.4B/$10.4B | -0.4% |
| Q2 2026 | $1.96/$1.86 | +5.4% | $10.1B/$10.0B | +1.9% |
PM beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest annual revenue by segment or product family
Tap, hover, or focus a slice to inspect segment detail.
Latest annual revenue by reported region
Tap, hover, or focus a slice to inspect segment detail.
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Fair value est. $135 — implies -18.8% from today's price.
| Metric | PM | S&P 500 | Consumer Defensive | 5Y Avg PM |
|---|---|---|---|---|
| Forward PE | 20.3x | 19.1x | 14.6x+39% | — |
| Trailing PE | 23.5x | 25.2x | 19.6x+20% | 20.2x+16% |
| PEG Ratio | 3.32x | 1.75x+90% | 1.85x+79% | — |
| EV/EBITDA | 18.3x | 15.3x+20% | 11.4x+60% | 14.8x+23% |
| Price/FCF | 24.9x | 21.3x+17% | 15.7x+58% | 17.7x+40% |
| Price/Sales | 6.5x | 3.1x+109% | 0.8x+673% | 5.0x+31% |
| Dividend Yield | 3.25% | 1.88% | 2.73% | 4.67% |
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolPM generates $10.7B in free cash flow at a 25.7% margin — 33.2% ROIC signals a durable competitive advantage · returns 3.2% of market cap to shareholders annually.
Revenue, margins, and cash generation
ROIC, leverage, and debt serviceability
~4.1 years to full repayment at current FCF run-rate
How capital is returned to owners
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageKey factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated April 11, 2026
Delays or unfavorable outcomes from the U.S. FDA for IQOS ILUMA and ZYN Ultra could stall near‑term U.S. growth. Heightened scrutiny over youth access to nicotine pouches and the strength of adolescent safety data further increases regulatory risk.
Emerging competitors are eroding IQOS market share in Japan, while Altria’s On! PLUS higher‑strength pouches directly compete with PM’s products. This could pressure pricing and volume in key markets.
Japan’s planned excise tax hikes of 10%–20% in April and October 2026 are expected to raise retail prices for IQOS, potentially dampening category growth, revenue, and profitability.
Significant U.S. market investments and inventory normalization efforts are tightening near‑term operating margins. These costs could offset revenue gains from new product launches.
A strengthening U.S. dollar can erode earnings growth, as a sizable portion of PM’s net sales come from foreign currencies.
PM’s price‑to‑earnings ratio of approximately 21.97 suggests it may be overvalued relative to earnings, potentially limiting upside if market sentiment shifts.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated April 11, 2026
Philip Morris is actively shifting its business model toward smoke‑free alternatives such as IQOS heated tobacco and ZYN nicotine pouches. This strategy is driving high single‑digit organic growth and expanding margins, with smoke‑free products already accounting for a significant portion of net revenues. The acquisition of Swedish Match has further bolstered its position in this growing category.
The company has demonstrated consistent year‑over‑year revenue growth, with smoke‑free products showing particularly strong expansion in both revenue and gross profit. Analysts project double‑digit EPS growth, supported by strong 2026 guidance. For instance, PM raised its 2025 outlook, projecting adjusted EPS growth of 12‑14% in dollar terms.
PM’s products are considered macro‑proof due to their addictive and habitual nature, making the company resilient to economic downturns and trade tensions. Its diversified exposure and product portfolio also contribute to this stability.
ZYN dominates the U.S. nicotine pouch market, providing a strong growth engine within the broader smoke‑free portfolio.
The company offers an attractive dividend yield, which is appealing to investors seeking income alongside growth.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
PM PM Philip Morris International Inc. | $265.8B | 20.3x | +7.0% | 26.7% | Buy | +10.0% |
MO MO Altria Group, Inc. | $117.3B | 12.4x | -2.6% | 36.9% | Buy | -2.4% |
BTI BTI British American Tobacco p.l.c. | $129.2B | 16.5x | -9.5% | -20.8% | Buy | -32.8% |
XXI XXII 22nd Century Group, Inc. | $621210 | — | +149.4% | -65.7% | — | — |
TPV TPVG TriplePoint Venture Growth BDC Corp. | $226M | 6.0x | +30.2% | — | Hold | +60.7% |
UVV UVV Universal Corporation | $1.3B | 12.9x | +14.1% | 4.2% | Buy | — |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
PM returns 3.2% total yield, led by a 3.25% dividend, raised 16 consecutive years.
Yield, cadence, and growth quality
How much per-share support comes from repurchases
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $1.47 | — | — | — |
| 2025 | $5.64 | +6.4% | 0.0% | 3.5% |
| 2024 | $5.30 | +3.1% | 0.0% | 4.4% |
| 2023 | $5.14 | +2.0% | 0.0% | 5.5% |
| 2022 | $5.04 | +2.9% | 0.1% | 5.1% |
Common questions answered from live analyst data and company financials.
Philip Morris International Inc. (PM) is rated Buy by Wall Street analysts as of 2026. Of 25 analysts covering the stock, 17 rate it Buy or Strong Buy, 7 rate it Hold, and 1 rate it Sell or Strong Sell. The consensus 12-month price target is $188, implying +10.0% from the current price of $171. The bear case scenario is $123 and the bull case is $221.
The Wall Street consensus price target for PM is $188 based on 25 analyst estimates. The high-end target is $205 (+20.2% from today), and the low-end target is $168 (-1.5%). The base case model target is $192.
PM trades at 20.3x times forward earnings. The stock's valuation is broadly in line with the broader market. Based on current multiples versus the peer group, the relative model signals overvalued. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
The primary risks for PM in 2026 are: (1) Regulatory Uncertainty — Delays or unfavorable outcomes from the U. (2) Market Competition — Emerging competitors are eroding IQOS market share in Japan, while Altria’s On! PLUS higher‑strength pouches directly compete with PM’s products. (3) Economic & Tax Headwinds — Japan’s planned excise tax hikes of 10%–20% in April and October 2026 are expected to raise retail prices for IQOS, potentially dampening category growth, revenue, and profitability. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
Analyst consensus estimates PM will report consensus revenue of $44.4B (+7.0% year-over-year) and EPS of $7.73 (+8.8% year-over-year) for the upcoming fiscal year. The following year, analysts project $47.8B in revenue.
A confirmed upcoming earnings date for PM is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
Philip Morris International Inc. (PM) generated $10.7B in free cash flow over the trailing twelve months — a free cash flow margin of 25.7%. PM returns capital to shareholders through dividends (3.2% yield) and share repurchases ($0 TTM).